The purpose of this survey is to provide the Canadian Cancer
Survivor Network (CCSN) with insights and perspectives about the use of
denosumab (Xgeva) for the prevention of skeletal-related events due to bone
metastases from solid tumours.
The information
gathered from this survey will be used in order to prepare a patient evidence
submission to the CADTH Common Drug Review. Please note that your personal
information is never shared or disclosed, but is used only by CCSN for input
for statistical purposes.
This survey will be open until noon on June 11, 2015 to enable us to prepare our patient evidence submission on June 16, 2015.
This survey will be open until noon on June 11, 2015 to enable us to prepare our patient evidence submission on June 16, 2015.
Access the survey at https://www.surveymonkey.com/s/2CK7HD9
No comments:
Post a Comment